Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Modalis TherapeuticsTSE:4883 20 EBIT per Share is 円-9.40 as of Dec. 2025. GuruFocus rates TSE:4883 with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 812 Drug Manufacturers companies, Modalis Therapeutics ranks better than 75.37% on this metric.
Modalis Therapeutics's EBIT per Share for the
three
months ended in Dec. 2025 was 円0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was 円-9.40.
During the past 3 years, the average EBIT per Share Growth Rate was 26.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -6.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Modalis Therapeutics's EBIT per Share or its related term are showing as below:
TSE:4883'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -76.3 Med: -29.65 Max: 26.1
Current: 26.1
During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Modalis Therapeutics was 26.10% per year. The lowest was -76.30% per year. And the median was -29.65% per year.
TSE:4883's 3-Year EBIT Growth Rate is ranked better than 75.37% of 812
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs TSE:4883: 26.10
Modalis Therapeutics (TSE:4883) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Modalis Therapeutics EBIT per Share Related Terms
Modalis Therapeutics EBIT per Share Historical Data
* Premium members only.
The historical data trend for Modalis Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-9.40
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Modalis Therapeutics (TSE:4883) has a EBIT per Share of 円-9.40 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Modalis Therapeutics and its competitors. According to the industry distribution chart, Modalis Therapeutics ranks #200 out of 812 companies in the Drug Manufacturers industry, placing it in the top 24.6%.
Is Modalis Therapeutics' EBIT per Share too high?
Modalis Therapeutics' current EBIT per Share is 円-9.40. Based on the distribution chart, Modalis Therapeutics ranks #200 out of 812 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Modalis Therapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Modalis Therapeutics' EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Modalis Therapeutics ranks #200 out of 812 companies for EBIT per Share. This places Modalis Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.45, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Modalis Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Modalis Therapeutics's current EBIT per Share is 円-9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Modalis Therapeutics stock overvalued right now?
Modalis Therapeutics (TSE:4883) has a current EBIT per Share of 円-9.40. The current EBIT per Share is 円-9.40. Modalis Therapeutics' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Modalis Therapeutics (TSE:4883), the current EBIT per Share is 円-9.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in the pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.
20GF Score
Get the complete analysis for TSE:4883
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4883 has been successfully added to your 
